In Eli Lilly's pivotal Phase 3 ATTAIN clinical trialsthe studies that led to FDA approvalparticipants taking orforglipron achieved average body weight reductions of approximately 7.9% to 8.7% over 36 to 40 weeks, depending on the dosing
Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D
However, some people who have conscious sedation fall asleep during the procedure
If the bacterial strains successfully colonize your gut, the effects could theoretically persist even after you stop taking the supplement, provided the dietary and lifestyle conditions that support those bacteria remain in place
Taken together, the GLP-1 experience illustrates both the promise and the limits of peptide pharmacology